Compare Mercadolibre Inc (MELI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs ResMed Inc. — how do they compare? Mercadolibre Inc trades at $1,889.25 (market cap $94.13B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: Mercadolibre Inc is far larger — about 3× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and ResMed Inc. for 51 Days on average.
| MELI | RMD | |
|---|---|---|
Market Cap | $94.13B | $31.89B |
Volume | 273,781 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $277.88 |
52-Week Low | $1.55K | $182.82 |
Typical Hold Time | 117 Days | 51 Days |
Enterprise Value | $101.77B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,873.57, up 0.04% on the day, with a bullish technical signal from moving averages and strong support near $1,813. The company reported $28.89B revenue in 2025, though net income margin dipped to 6.91%, and recent earnings show mixed results with a beat in Q2 2026 but misses in prior quarters. Analyst consensus is strongly positive with a $2,170 price target, and cash flow from operations surged to $12.12B in 2025, underscoring robust financial health.
Outlook remains favorable due to dominant e-commerce and fintech positioning in Latin America, with revenue projected to hit $35.2B in 2026. Risks include profit margin pressures and macroeconomic volatility in key markets like Argentina. Institutional sentiment is bullish, with 73% of analysts rating it Buy, supporting potential upside near all-time highs.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
